https://www.selleckchem.com/products/MLN-2238.html
Thirty-one patients, 48% with ≥4 lines of previous therapies, were treated and evaluable. ORR was 9.7% (95% CI 0 to 28) and stable disease (SD) 67.7% (95% CI 50 to 85). OR/SD ≥4 months was associated with higher HER2 immunohistochemistry score (3+ vs 2+) (p = 0.03). Median PFS was 4.1 months (95% CI 3.6 to 5.9). Drug-related grade (G) 3 adverse events were observed in two patients (thrombocytopaenia); G≤2 AE in 84% of cycles (n = 296), mainly nausea and fatigue. HERACLES-B trial did not reach its primary end point of ORR; however, base
پسند
تبصرہ
بانٹیں
